Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 13/20 | 0.78 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25656161 | 0.91 | ENPP1 (0.65) | ENPP1AURKAACHEBACE1PDGFRB | |
| SCHEMBL25656170 | 0.90 | ENPP1 (0.79) | ENPP1AURKAACHEBACE1PDGFRB | |
| SCHEMBL23742849 | 0.88 | ENPP1 (1.00) | ENPP1AURKAACHEBACE1PDGFRB | |
| Hydrochloric Acid SCHEMBL30117239 | 0.87 | ENPP1 (0.98) | ENPP1AURKAACHEBACE1PDGFRB | |
| Hydrochloric Acid SCHEMBL23726073 | 0.87 | ENPP1 (0.98) | ENPP1AURKAACHEBACE1PDGFRB | |
| SCHEMBL25655998 | 0.85 | ENPP1 (0.61) | ENPP1AURKAACHEBACE1PDGFRB | |
| SCHEMBL25656162 | 0.84 | ENPP1 (0.56) | ENPP1AURKAACHEBACE1PDGFRB | |
| SCHEMBL25656014 | 0.84 | ENPP1 (0.63) | ENPP1 | |
| SCHEMBL25656001 | 0.83 | ENPP1 (0.66) | ENPP1AURKAACHEBACE1PDGFRB | |
| SCHEMBL20771431 | 0.83 | ENPP1 (0.93) | ENPP1AURKAACHEBACE1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PPA1 | ENPP1 1/4885AURKA 3497/4885ACHE 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.